[1]
|
Duan, S., Zhang, Y. and Xu, S. (2022) Contrast-Enhanced Ultrasound Parameters and D-Dimer: New Prognostic Pa-rameters for Diffuse Large B-Cell Lymphoma. Cancer Management and Research, 14, 2535-2544.
https://doi.org/10.2147/CMAR.S326173
|
[2]
|
Li, S., Young, K.H. and Medeiros, L.J. (2018) Diffuse Large B-Cell Lymphoma. Pathology, 50, 74-87.
https://doi.org/10.1016/j.pathol.2017.09.006
|
[3]
|
杨铭, 张清媛. 外周血检测指标在弥漫大B细胞淋巴瘤预后评估中应用价值的研究进展[J]. 癌症进展, 2020, 18(7): 657-660.
|
[4]
|
Geng, Y.D., Chen, Y.R. and Jin, J. (2019) Prognostic Value of D-Dimer in Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Study. Current Medical Science, 39, 222-227. https://doi.org/10.1007/s11596-019-2023-5
|
[5]
|
Dehghani, M., Kalani, M. and Golmoghad-dam, H. (2020) Aberrant Peripheral Blood CD4(+) CD25(+) FOXP3(+) Regulatory T Cells/T Helper-17 Number Is Associated with the Outcome of Patients with Lymphoma. Cancer Immunology, Immunotherapy, 69, 1917-1928. https://doi.org/10.1007/s00262-020-02591-y
|
[6]
|
熊婕妤, 罗明青. NLR和PLR对弥漫大B细胞淋巴瘤患者预后的影响[J]. 重庆医学, 2020, 49(21): 3520-3525.
|
[7]
|
Zhao, P., Zang, L. and Zhang, X. (2018) Novel Prognostic Scoring System for Diffuse Large B-Cell Lymphoma. Oncology Letters, 15, 5325-5332. https://doi.org/10.3892/ol.2018.7966
|
[8]
|
Chen, Y., Zhang, Z. and Fang, Q. (2019) Prognostic Impact of Plate-let-to-Lymphocyte Ratio on Diffuse Large B-Cell Lymphoma: A Meta-Analysis. Cancer Cell International, 19, Article No. 245.
https://doi.org/10.1186/s12935-019-0962-3
|
[9]
|
Yang, J., Liao, D. and Chen, C. (2013) Humor-Associated Mac-rophages Regulate Murine Breast Cancer Stem Cells through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway. Stem Cells, 31, 248-258.
https://doi.org/10.1002/stem.1281
|
[10]
|
Hong, J.Y., Ryu, K.J. and Lee, J.Y. (2017) Serum Level of CXCL10 Is Associated with Inflammatory Prognostic Biomarkers in Patients with Diffuse Large B-Cell Lymphoma. Hematological Oncology, 35, 480-486.
https://doi.org/10.1002/hon.2374
|
[11]
|
Wu, J., Zhu, H. and Zhang, Q. (2022) Nomogram Based on the Systemic Immune-Inflammation Index for Predicting the Prognosis of Diffuse Large B-Cell Lymphoma. Asia-Pacific Journal of Clinical Oncology, 19, e138-e148.
https://doi.org/10.1111/ajco.13806
|
[12]
|
Wang, S., Ma, Y. and Sun, L. (2018) Prognostic Significance of Pretreat-ment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma. BioMed Research International, 2018, Article ID: 9651254. https://doi.org/10.1155/2018/9651254
|
[13]
|
Menter, D.G., Tucker, S.C. and Kopetz, S. (2014) Platelets and Cancer: A Casual or Causal Relationship: Revisited. Cancer and Metastasis Reviews, 33, 231-269. https://doi.org/10.1007/s10555-014-9498-0
|
[14]
|
Wang, J., Zhou, X. and Liu, Y. (2017) Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Diffuse Large B-Cell Lymphoma: A Me-ta-Analysis. PLOS ONE, 12, e0176008. https://doi.org/10.1371/journal.pone.0176008
|
[15]
|
李敬东, 韩效林, 杨翠. DLBCL患者CHOP或R-CHOP化疗前后中性粒细/淋巴细胞比值的变化及其对生存的影响[J]. 中国实验血液学杂志, 2018, 26(1): 182-186.
|
[16]
|
杨梦珠. 弥漫大B细胞淋巴瘤患者外周血NLR、PLR以及LDH的水平及其临床意义[D]: [硕士学位论文]. 新乡: 新乡医学院, 2021.
|
[17]
|
张林艳. 中性粒细胞/淋巴细胞比值对弥漫大B细胞淋巴瘤患者的预后价值[D]: [硕士学位论文]. 太原: 山西医科大学, 2019.
|
[18]
|
刘佳为. 中性粒细胞-淋巴细胞比值和血小板-淋巴细胞比值对弥漫大B细胞淋巴瘤的预后价值[D]: [硕士学位论文]. 济南: 山东大学, 2020.
|
[19]
|
朱明, 李延莉, 王芝涛. 弥漫大B细胞淋巴瘤患者中性粒细胞/淋巴细胞比值与疗效及预后的关系[J]. 白血病∙淋巴瘤, 2015, 24(8): 460-463.
|
[20]
|
Choi, M., Lee, J.O. and Jung, J. (2019) Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma. Acta Haematologica, 141, 176-186. https://doi.org/10.1159/000495337
|
[21]
|
Wu, X.B., Hou, S.L. and Liu, H. (2021) Systemic Immune Inflammation Index, Ratio of Lymphocytes to Monocytes, Lactate Dehydrogenase and Prognosis of Diffuse Large B-Cell Lymphoma Patients. World Journal of Clinical Case Reports, 9, 9825-9834. https://doi.org/10.12998/wjcc.v9.i32.9825
|
[22]
|
Wang, Z., Zhang, J. and Luo, S. (2021) Prognostic Significance of Systemic Immune-Inflammation Index in Patients with Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 11, Ar-ticle ID: 655259.
https://doi.org/10.3389/fonc.2021.655259
|
[23]
|
Chen, L., Kong, X. and Wang, Z. (2020) Pre-Treatment Systemic Immune-Inflammation Index Is a Useful Prognostic Indicator in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Journal of Cellular and Molecular Medicine, 24, 2993-3021. https://doi.org/10.1111/jcmm.14934
|
[24]
|
Tong, Y.S., Tan, J. and Zhou, X.L. (2017) Systemic Im-mune-Inflammation Index Predicting Chemoradiation Resistance and Poor Outcome in Patients with Stage III Non-Small Cell Lung Cancer. Journal of Translational Medicine, 15, Article No. 221. https://doi.org/10.1186/s12967-017-1326-1
|
[25]
|
陈娟, 石志, 娄慧娟. 系统免疫-炎症指数对初诊多发性骨髓瘤患者预后的评估价值[J]. 临床血液学杂志, 2022, 35(3): 180-186.
|
[26]
|
郑永青, 孙明东, 王瑞芳. 血清β_2-MG联合LDH在弥漫性大B细胞淋巴瘤预后判断中的意义[J]. 疑难病杂志, 2022, 21(6): 582-587.
|
[27]
|
张青, 李承彬, 邓明凤. 弥漫大B细胞性淋巴瘤患者Ki-67、β2-MG、CRP、ESR的水平变化及意义[J]. 微循环学杂志, 2021, 31(2): 57-61.
|
[28]
|
刘文涛. β2-MG、IL-17及VEGF水平表达对多发性骨髓瘤患者疾病进展及预后的影响[J]. 新疆医学, 2022, 52(6): 632-634.
|
[29]
|
于明雪, 刘加军. 高β2微球蛋白对弥漫大B细胞淋巴瘤的临床意义[J]. 蚌埠医学院学报, 2020, 45(8): 1040-1043.
|
[30]
|
卢丹, 胡艳, 袁韵. 弥漫大B细胞淋巴瘤患者血清β_2-MG水平与预后的关系[J]. 标记免疫分析与临床, 2020, 27(12): 2059-2062.
|
[31]
|
熊丽丽. 血清LDH、β_2-MG、CA125水平变化与弥漫大B细胞淋巴瘤患者临床分期、疾病转归的关联性探究[J]. 医学理论与实践, 2022, 35(10): 1748-1750.
|
[32]
|
黄天骄, 周虹, 刘松涛. 弥漫大B细胞淋巴瘤患者血清中乳酸脱氢酶、β2微球蛋白及尿酸临床意义[J]. 临床血液学杂志, 2021, 34(6): 412-414.
|
[33]
|
李青芬, 张启科, 魏小芳. 多发性骨髓瘤患者凝血指标水平及预后意义[J]. 中国实验血液学杂志, 2021, 29(3): 791-796.
|
[34]
|
卜广瑞, 张艳敏, 徐李红. 多发性骨髓瘤患者的凝血指标变化及临床意义[J]. 血栓与止血学, 2022, 28(3): 450-451+453.
|
[35]
|
Liu, B., Li, B. and Zhou, P. (2018) Prognostic Value of Pretreatment Plasma D-Dimer Levels in Patients with Diffuse Large B Cell Lymphoma (DLBCL). Clinica Chimica Acta, 482, 191-198. https://doi.org/10.1016/j.cca.2018.04.013
|
[36]
|
Huang, H., Fan, L. and Fu, D. (2021) High Pretreatment Plasma D-Dimer Levels Predict Poor Survival in Patients with Diffuse Large B-Cell Lymphoma in the Real World. Translational Cancer Research, 10, 1723-1731.
https://doi.org/10.21037/tcr-20-2908
|
[37]
|
刘文洁, 李兰竹, 孙倩. D-二聚体/纤维蛋白原比值在急性髓系白血病患者中的临床意义分析[J]. 临床肿瘤学杂志, 2021, 26(12): 1079-1084.
|
[38]
|
叶韬, 宋红蕾, 胡岳棣. 血浆D-二聚体评估非霍奇金淋巴瘤疗效的价值[J]. 现代肿瘤医学, 2016, 24(17): 2765-2768.
|
[39]
|
Gradel, K.O., Larsen, T.S. and Frederiksen, H. (2022) Impact of C-Reactive Protein and Albumin Levels on Short, Medium, and Long-Term Mor-tality in Patients with Diffuse Large B-Cell Lymphoma. Annals of Medicine, 54, 713-722. https://doi.org/10.1080/07853890.2022.2046287
|
[40]
|
Qin, W., Yuan, Q. and Wu, J. (2019) Prognostic Value of Pre-Therapy C-Reactive Protein Level in Diffuse Large B-Cell Lymphoma: A Meta-Analysis. Leukemia & Lymphoma, 60, 358-366.
https://doi.org/10.1080/10428194.2018.1482540
|
[41]
|
黄琴, 王增胜, 李燕. 血清C反应蛋白在弥漫大B细胞淋巴瘤预后中的意义[J]. 肿瘤研究与临床, 2016, 28(4): 244-247.
|
[42]
|
潘必慧, 孔祎琳, 王莉. C反应蛋白/白蛋白比值在弥漫大B细胞淋巴瘤患者中的预后价值[J]. 南京医科大学学报(自然科学版), 2020, 40(2): 228-233.
|
[43]
|
何昕, 高海燕, 姜永芳. 血清C-反应蛋白对弥漫大B淋巴瘤患者预后评估及相关性分析[J]. 标记免疫分析与临床, 2017, 24(8): 856-858.
|
[44]
|
何婧, 施文瑜. 血清载脂蛋白C1、C反应蛋白及白介素6水平在弥漫大B细胞淋巴瘤诊断中的预测价值[J]. 交通医学, 2022, 36(1): 1-9.
|